Novartis Venture Fund

General contacts

Investor type

CVC / VC

Founded

1996

AUM

$750 M

Location

Basel, Basel-Stadt, Switzerland

Investment Ticket

$10-50 m

Investment Stage

Series B Series A Seed Late Stage (Series C+)

Region of investment

North America Europe

ESG Focus

Impact investor

Investor profile last updated: 28 August, 2026

Profile

Novartis Venture Fund is a life science investor with bases in Basel, Switzerland, and Cambridge, Massachusetts. The fund focuses on fostering innovation and generating returns by investing in life science companies. With a team experienced in drug development, they take a hands-on approach to their investments, working closely with management to create clinical impact.

The fund invests in biotechnology and biopharmaceuticals at various stages of growth. They manage over USD 750 million in committed capital and have more than 40 portfolio companies across North America and Europe. Their investment strategy emphasizes developing novel therapeutics and platforms that address unmet patient needs in healthcare.

Notable investments include companies such as: Amgen - biotechnology leader, Alnylam Pharmaceuticals - RNA interference therapies, and Editas Medicine - gene editing technology. Other portfolio companies include: Zymeworks - therapeutic proteins, and Alector - immune-mediated diseases.

Industry

Life Sciences Technology MedTech Software Pharmaceuticals HealthTech Medical Devices Healthcare Services Digital Biotechnology

Novartis Venture Fund Funds

Name	Type	Industry	Stage	Region	Size	AUM	Launch date
Novartis Korea Venture Fund	Fund of funds	Biotechnology Pharmaceuticals Life Sciences HealthTech	Seed Series A Series B Late Stage (Series C+)	North America Europe	$5-10 m	$20 M	January 2008
Novartis Option Fund	Fund of funds	Biotechnology Pharmaceuticals Life Sciences HealthTech	Seed Series A Series B Late Stage (Series C+)	North America Europe	$5-10 m	$200 M	January 2009

Contacts

Name

Title

Social Networks

Dr. Marianne Uteng Principal

Principal

m•••@•••

Dr. Laura Brass Managing Director

Managing Director

l•••@•••

Upgrade to see contacts

xsGHnFNQfW0DyrLA xsGHnFNQfW0DyrLA

xsGHnFNQfW0DyrLA

[email protected]

xsGHnFNQfW0DyrLA xsGHnFNQfW0DyrLA

xsGHnFNQfW0DyrLA

[email protected]

xsGHnFNQfW0DyrLA xsGHnFNQfW0DyrLA

xsGHnFNQfW0DyrLA

[email protected]

Investment-team contacts for Novartis Venture Fund — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.

Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Novartis Venture Fund

Is Novartis Venture Fund a venture capital or private equity firm?

Novartis Venture Fund is a venture capital firm that also operates as a corporate VC (CVC). It backs companies at Series B, Series A, Seed and Late Stage (Series C+), writing tickets of $10-50 m.

Where is Novartis Venture Fund located?

Novartis Venture Fund is located in Basel, Basel-Stadt, Switzerland.

When was Novartis Venture Fund founded?

Novartis Venture Fund was founded in 1996.

What sectors and industries does Novartis Venture Fund invest in?

Novartis Venture Fund invests in companies and startups in Life Sciences, Technology, MedTech, Software, Pharmaceuticals, HealthTech, Medical Devices, Healthcare Services, Digital, Biotechnology.

What is Novartis Venture Fund geographical focus of investments?

Novartis Venture Fund invests in companies and startups in North America, Europe.

At what stages of companies and startups does Novartis Venture Fund typically invest in?

Novartis Venture Fund invests in companies and startups at Series B, Series A, Seed, Late Stage (Series C+).

What is the usual amount of Novartis Venture Fund investment?

Novartis Venture Fund usually invests $10-50 m on average.

What is the amount of assets of under management (AUM) for Novartis Venture Fund?

Novartis Venture Fund has around $750m assets under management.

When was Novartis Venture Fund last fund created?

Novartis Venture Fund last fund was created/launched in 2009-01-16

Is Novartis Venture Fund impact investor?

Yes, Novartis Venture Fund is impact investor.

What are the contacts of Novartis Venture Fund?

Novartis Venture Fund can be reached through its website nvfund.com, its LinkedIn page and its X account. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Novartis Venture Fund — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

Can I access Novartis Venture Fund data via API or MCP?

Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Novartis Venture Fund directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.

When was the Novartis Venture Fund profile last updated?

Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 28 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.